ClinicaliQ Trial Snapshot
- A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) — Recruiting • Phase III • Gastroenterology • NCT06318169.
- What is being tested: Pegozafermin (a FGF21 analogue) at two different dose regimens versus placebo for treating liver fibrosis (stages F2–F3) in adults with metabolic dysfunction-associated steatohepatitis (MASH).
- Patient eligibility overview: Adult participants with confirmed MASH diagnosis and fibrosis staging of F2 or F3, excluding more advanced cirrhosis (F4) and those with decompensated liver disease.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.
Eligibility Snapshot
- Key Inclusion Criteria: * Males or non-pregnant females aged between 18 and 80 years (inclusive) at time of signing the informed consent form (ICF) * Biopsy-confirmed MASH with fibrosis stage F2 or F3 * Body mass index (BMI) at screening ≥25.0 kilograms (kg)/meters squared (m^2) (≥23 kg/m^2 for Asian participants). Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.